Morgan Stanley Biovie Inc. Transaction History

Morgan Stanley

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.4 - $0.56 $4,892 - $6,849	-12,232 Reduced 49.72%	12,369 $4,000
Q2 2024 Aug 14, 2024	SELL	$0.4 - $0.56 $4,892 - $6,849	-12,232 Reduced 49.72%	12,369 $4,000
Q1 2024 Oct 17, 2024	BUY	$0.53 - $1.89 $6,482 - $23,118	12,232 Added 98.89%	24,601 $13,000
Q1 2024 Aug 16, 2024	SELL	$0.53 - $1.89 $30,964 - $110,421	-58,424 Reduced 70.37%	24,601 $13,000
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $30,964 - $110,421	-58,424 Reduced 70.37%	24,601 $13,000
Q4 2023 Aug 16, 2024	BUY	$1.22 - $5.24 $86,200 - $370,237	70,656 Added 571.23%	83,025 $104,000
Q4 2023 Feb 13, 2024	BUY	$1.22 - $5.24 $33,791 - $145,137	27,698 Added 50.06%	83,025 $104,000
Q3 2023 Nov 15, 2023	BUY	$2.75 - $5.17 $50,941 - $95,769	18,524 Added 50.33%	55,327 $188,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $38,625 - $78,290	9,444 Added 34.52%	36,803 $158,000
Q1 2023 May 15, 2023	BUY	$4.89 - $10.53 $24,503 - $52,765	5,011 Added 22.42%	27,359 $221,000
Q4 2022 Feb 14, 2023	BUY	$3.86 - $42.0 $78,145 - $850,290	20,245 Added 962.67%	22,348 $173,000
Q3 2022 Nov 14, 2022	BUY	$1.38 - $25.6 $832 - $15,436	603 Added 40.2%	2,103 $5,000
Q1 2022 May 13, 2022	SELL	$2.74 - $5.65 $5 - $11	-2 Reduced 0.13%	1,500 $7,000
Q4 2021 Feb 14, 2022	BUY	$4.41 - $6.99 $6,271 - $9,939	1,422 Added 1777.5%	1,502 $7,000
Q3 2021 Nov 15, 2021	BUY	$6.69 - $16.93 $535 - $1,354	80 New	80 $1,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $92M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.